SCHEMBL20148733

SCHEMBL20148733

Cc1ccc(C(=O)N2C3CC2CN(C(C)C)C3)cc1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
HSD11B1 P28845 1/20 0.40
RET P07949 1/20 0.40
CHRM1 P11229 1/20 0.39
KMT2A Q03164 4/20 0.39
ALDH1A1 P00352 3/20 0.39
LMNA P02545 2/20 0.39
HTT P42858 2/20 0.39
KCNQ3 O43525 2/20 0.38
KCNQ2 O43526 2/20 0.38
KCNE1 P15382 2/20 0.38
KCNQ1 P51787 2/20 0.38
MEN1 O00255 2/20 0.37
TP53 P04637 1/20 0.37
TSHR P16473 1/20 0.37
KDM1A O60341 1/20 0.37
CNR2 P34972 1/20 0.37
KCNQ5 Q9NR82 1/20 0.36
TLR9 Q9NR96 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20070592 0.85 HDAC1 (0.44) HDAC1HDAC6HSD11B1RETCHRM1
SCHEMBL18389842 0.84 CPS1 (0.48) RETKMT2AALDH1A1LMNAHTT
SCHEMBL20152351 0.82 RET (0.43) HDAC1HDAC6HSD11B1RETCHRM1
SCHEMBL20160507 0.77 RET (0.42) HDAC1HDAC6HSD11B1RETCHRM1
SCHEMBL20148699 0.76 HPGD (0.48) RETALDH1A1TP53KDM1A
SCHEMBL20148734 0.76 HPGD (0.54) KMT2AALDH1A1MEN1TSHR
SCHEMBL20148711 0.75 HDAC1 (0.40) HDAC1HDAC6RETKMT2AALDH1A1
SCHEMBL18705128 0.75 RET (0.46) RET
SCHEMBL20148732 0.75 KMT2A (0.47) RETKMT2AALDH1A1LMNAHTT
SCHEMBL17559438 0.75 PRMT5 (0.47) HDAC1HDAC6HSD11B1CHRM1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240066029-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2024-02-29 US disclosed
US-10555944-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ELI LILLY AND COMPANY (US) 2020-02-11 US disclosed
US-10172851-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2019-01-08 US disclosed
US-20180133213-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed
US-20180133200-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed
US-20180133213-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10555944-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, ROR1, BRAF HDAC1 1405/4885HDAC6 2652/4885HSD11B1 2343/4885
US-20180133200-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF HDAC1 1405/4885HDAC6 2652/4885HSD11B1 2343/4885
US-10172851-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, ROR1, BRAF HDAC1 1405/4885HDAC6 2652/4885HSD11B1 2343/4885
US-20180133213-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF HDAC1 1405/4885HDAC6 2652/4885HSD11B1 2343/4885
US-20240066029-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF HDAC1 1405/4885HDAC6 2652/4885HSD11B1 2343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.